Following a limited submission
AWMSG advice |
|
| Status: Terminated | |
Maintenance treatment of adults with asthma not adequately controlled with a combination of medium or high dose inhaled corticosteroid and long-acting beta-2 agonist. |
|
Medicine details |
|
| Medicine name | fluticasone furoate/umeclidinium/vilanterol (Trelegy® Ellipta®) |
| Formulation | 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed and 184 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed |
| Reference number | 3620 |
| Indication | As above |
| Company | GlaxoSmithKline UK |
| BNF chapter | Respiratory system |
| Submission type | Limited |
| Status | Terminated |
| NMG meeting date | 28/02/2024 |
| AWMSG meeting date | 11/06/2024 (provisional) |
| Date of issue | TBC |